Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.42 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | GCK | P35557 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23093167 | 1.00 | PTGS2 (0.42) | PTGS2JAK2HDAC6GCKAURKA | |
| SCHEMBL23093039 | 1.00 | PTGS2 (0.42) | PTGS2JAK2HDAC6GCKAURKA | |
| SCHEMBL23093187 | 0.75 | PTGS2 (0.45) | PTGS2JAK2HDAC6 | |
| SCHEMBL29802485 | 0.71 | PTGS2 (0.42) | PTGS2JAK2HDAC6 | |
| SCHEMBL23093152 | 0.71 | PTGS2 (0.42) | PTGS2JAK2HDAC6 | |
| SCHEMBL5738793 | 0.67 | PTGS2 (0.49) | PTGS2HDAC6 | |
| SCHEMBL3401229 | 0.64 | JAK2 (0.45) | PTGS2JAK2HDAC6AURKACDK4 | |
| SCHEMBL1657463 | 0.61 | JAK2 (0.65) | PTGS2JAK2HDAC6AURKACDK4 | |
| SCHEMBL3247760 | 0.59 | PTGS2 (1.00) | PTGS2 | |
| SCHEMBL1384962 | 0.59 | TSHR (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220348590-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BOARD INSTITUTE, INC. (US) | 2022-11-03 | — | — | US | disclosed |
| EP-4027993-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | The Broad Institute Inc. (US) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021050700-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220348590-A1 | CYCLOOXYGENASE-2 INHIBITORS AND USES THEREOF | PTGES2, PTGS2, PTGES | PTGS2 2/4885JAK2 608/4885HDAC6 3230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.